- Q3 2024 Zydus Lifesciences Ltd Earnings Call TranscriptFeb 09, 2024Earnings
- Q2 2024 Zydus Lifesciences Ltd Earnings Call TranscriptNov 07, 2023Earnings
- Q1 2024 Zydus Lifesciences Ltd Earnings Call TranscriptAug 11, 2023Earnings
- Q4 2023 Zydus Lifesciences Ltd Earnings Call TranscriptMay 18, 2023Earnings
- Q3 2023 Zydus Lifesciences Ltd Earnings Call TranscriptFeb 03, 2023Earnings
- Q2 2023 Zydus Lifesciences Ltd Earnings Call TranscriptNov 11, 2022Earnings
- Q1 2023 Zydus Lifesciences Ltd Earnings Call TranscriptAug 10, 2022Earnings
- Q4 2022 Zydus Lifesciences Ltd Earnings Call TranscriptMay 20, 2022Earnings
- Cadila Healthcare Ltd Extraordinary Shareholders Meeting TranscriptFeb 18, 2022
- Q3 2022 Cadila Healthcare Ltd Earnings Call TranscriptFeb 03, 2022Earnings
- Q2 2022 Cadila Healthcare Ltd Earnings Call TranscriptOct 29, 2021Earnings
- Cadila Healthcare Ltd to Discuss About the Emergency Use Authorization of ZyCov-D Vaccine Call TranscriptAug 23, 2021
- Q1 2022 Cadila Healthcare Ltd Earnings Call TranscriptAug 11, 2021Earnings
- Q4 2021 Cadila Healthcare Ltd Earnings Call TranscriptMay 27, 2021Earnings
- Cadila Healthcare Ltd to Discuss the Transaction of Zydus Cadila Entity to Sell Its India Focused Animal Health Business to Multiples Alternate Asset Management Call TranscriptMay 12, 2021
- Q3 2021 Cadila Healthcare Ltd Earnings Call TranscriptFeb 05, 2021Earnings
- Q2 2021 Cadila Healthcare Ltd Earnings Call TranscriptNov 02, 2020Earnings
- Q1 2021 Cadila Healthcare Ltd Earnings Call TranscriptAug 05, 2020Earnings
- Q4 2020 Cadila Healthcare Ltd Earnings Call TranscriptJun 19, 2020Earnings
- Q3 2020 Cadila Healthcare Ltd Earnings Call TranscriptFeb 05, 2020Earnings
- Q2 2020 Cadila Healthcare Ltd Earnings Call TranscriptNov 13, 2019Earnings
- Q1 2020 Cadila Healthcare Ltd Earnings Call TranscriptAug 09, 2019Earnings
- Q4 2019 Cadila Healthcare Ltd Earnings Call TranscriptMay 29, 2019Earnings
Q2 2024 Zydus Lifesciences Ltd Earnings Call Transcript
(technical difficulty)
For today's call we have Dr. Sharvil Patel Managing Director; Mr. Nitin Parekh, Chief Financial Officer; Mr. Arvind Bothra, Senior Vice President, Investor Relations; and Mr. Alok Garg Senior Vice President from the Managing Director's office. Now let me give you a broad overview of the developments during the quarter.
In terms of overall revenues, we registered stable growth of 9% during the quarter. Our Branded Formulations business in India grew in a single high digit after adjusting for impact of NLEM and partly affected by delay in the acute season. The U.S. Formulations business performed on expected lines, driven by a stable base business and supported by new introductions. Our Emerging Markets and Europe Formulations businesses continued growth momentum and delivered double-digit growth.
Our network of regulatory-compliant manufacturing facilities and a resilient supply chain serves as the backbone of our globally -- global business. We remain committed to extend our
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)